Japan· JP-6132700J1022
セフチゾキシムナトリウム
A ceftizoxime product containing セフチゾキシムナトリウム, registered in Japan by 長生堂製薬, on the national reimbursement list. The same ATC class is registered in 2 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Ceftizoxime is registered in 2 of 19 countries.
Countries holding a registration under ATC J01DD07 (ceftizoxime), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 1 of them publish a price we can compare per daily dose
Ceftizoxime · ATC J01DD07
2 / 19 countries
- Finlandprice
- Japan
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- セフチゾキシムナトリウム
- Manufacturer
- 長生堂製薬
- Country
- Japan (JP)
- ATC code
- J01DD07
- ATC class
- Ceftizoxime
- Defined daily dose
- 4 g, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
19 interactions on record for ceftizoxime.
Graded by severity as the source publishes them — 19 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ceftizoxime · interactions on record
19 records
- 19 moderate
Most severe, free to view
- Sodium picosulfateA06AB08moderate
- NeomycinA07AA01moderate
- StreptomycinA07AA04moderate
- KanamycinA07AA08moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J01DD07
Ceftizoxime, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4cb1b3b6-d84b-4bc8-a59f-79061b02e6cc GET /v1/drugs/4cb1b3b6-d84b-4bc8-a59f-79061b02e6cc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１２５ｍｇ１個",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "6132700J1022",
"category": "外用薬",
"price_yen": 223.3,
"generic_name": "セフチゾキシムナトリウム",
"product_name_jp": null,
"therapeutic_class": "6132",
"transitional_expiry": null
}See everything about ceftizoxime.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.